Previous 10 | Next 10 |
Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting PR Newswire SAN DIEGO , March 3, 2023 ...
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide ther...
Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference PR Newswire SAN DIEGO , Feb. 7, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual SVB Securities Global Biopharma Conference at 12:00 ...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Neurocrine Biosciences, Inc. 2022 Q4 - Results - Earnings Call Presentation
Start Time: 08:00 End Time: 09:02 Neurocrine Biosciences, Inc. (NBIX) Q4 2022 Earnings Conference Call February 06, 2023, 08:00 AM ET Company Participants Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief ...
Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q4 Non-GAAP EPS of $1.24 misses by $0.20 . Revenue of $412M (+32.1% Y/Y) beats by $3.04M . INGREZZA fourth quarter and fiscal 2022 net product sales were $399 million and $1.43 billion, respectively INGREZZA ...
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023 PR Newswire INGREZZA ® (valbenazine) Fourth Quarter Net Product Sales of $399 Million INGREZZA ® (valbenazine) 2023 ...
Summary Neurocrine Biosciences is a pharmaceutical company specializing in the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company recently submitted a proposal for the use of Ingrezza as a treatment for Huntington's chorea. Ingrezza, with its clin...
Neurocrine Biosciences ( NASDAQ: NBIX ) added ~4% pre-market Friday after Morgan Stanley upgraded the commercial-stage drug developer to Overweight from Equal Weight, citing FDA approval for its lead asset Ingrezza for Huntington's disease chorea. Ingrezza is already approved in t...
Summary Expect strong Neurocrine Biosciences, Inc. Q4 results on February 6, 2023. Two important pipeline results regarding congenital adrenal hyperplasia and focal onset seizures will be coming this February. The FDA accepted Neurocrine Biosciences' sNDA for valbenazine as a treatm...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $170.00 for NBIX on 2024-07-12 08:10:00. The adjusted price target was set to $170.00. At the time of the announcement, NBIX was trading at $146.5. The overall price target consensus is at $...
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results PR Newswire Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO , July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasd...